Pharming Group NV (PHARM) Ordinary EUR0.01

Sell:€0.71Buy:€0.72€0.03 (4.05%)

Prices delayed by at least 15 minutes
Sell:€0.71
Buy:€0.72
Change:€0.03 (4.05%)
Prices delayed by at least 15 minutes
Sell:€0.71
Buy:€0.72
Change:€0.03 (4.05%)
Prices delayed by at least 15 minutes

Company Information

About this company

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Key people

Fabrice Chouraqui
Chief Executive Officer, Executive Director
Jeroen Wakkerman
Chief Financial Officer
Mireille Sanders
Chief Operations Officer
Ruud van Outersterp
Chief Ethics and Compliance Officer
Alexander Breidenbach
Chief Business Officer
Anurag Relan
Chief Medical Officer
Stephen Toor
Chief Commercial Officer
Richard Peters
Non-Executive Independent Chairman of the Board
Deborah Ann Jorn
Non-Executive Independent Vice Chairman of the Board
Steven Baert
Non-Executive Independent Director
Leonard Kruimer
Non-Executive Independent Director
Mark J. Pykett
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    PHARM
  • Location
    Netherlands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0010391025
  • Market cap
    €503.43m
  • Employees
    415
  • Shares in issue
    678.54m
  • Exchange
    Euronext Amsterdam Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.